President Trump and Democrat lawmakers are discussing allowing Medicare to negotiate drug prices directly with manufacturers, and the idea is popular with voters. While it seems intuitive that negotiations should lead to lower drug costs, the truth is far less clear. The nonpartisan Congressional Budget Office has predicted that negotiations will lead to minimal savings, yet other governments who negotiate with manufacturers pay less for drugs than the US.
Join us April 3 for an expert panel discussion of the role of the US government in price negotiations.
- Event Date
- Monday, April 03, 2017
10:30 AM - 11:45 AM Pacific - Location
- Ronald Tutor Campus Center, The Forum
University of Southern California
Panel
- Sir Michael Rawlins, Chair of the UK Medicines and Healthcare Products Regulatory Agency, and former chair of the National Institute for Health and Care Excellence in the UK
- Neeraj Sood, Professor & Vice Dean for Research at the USC Sol Price School of Public Policy and Director of Research at the USC Schaeffer Center for Health Policy and Economics
- David Lazarus, award-winning business columnist for the Los Angeles Times, focusing on consumer affairs
- Dana Goldman (moderator), Professor and the Leonard D. Schaeffer Chair and Director of the USC Schaeffer Center for Health Policy and Economics